Newsroom
Keep up with the latest
Featured
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Scribe Therapeutics Highlights Data Underpinning its Comprehensive Strategy Targeting Key Lipid Drivers of ASCVD at American Heart Association (AHA) Scientific Sessions 2025
November 17, 2025
Epigenetic editors are a gentler form of gene editing
February 24, 2025
The Economist
Epigenetic editors are a gentler form of gene editing
February 24, 2025
Media Center
Media
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
May 16, 2023
Fierce Biotech
Read Now
Press Release
Scribe's CRISPR tech Prevails in new $1.5B biobucks deal with Lilly unit
May 16, 2023
Fierce Biotech
Read Now
Media
Scribe pens $1.5B-plus CRISPR tech deal with Lilly
May 16, 2023
BioWorld
Read Now
Press Release
Scribe pens $1.5B-plus CRISPR tech deal with Lilly
May 16, 2023
BioWorld
Read Now
Media
Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal
May 16, 2023
Seeking Alpha
Read Now
Press Release
Lilly, Scribe team up for neuro diseases CRISPR therapies in $75M upfront cash/equity deal
May 16, 2023
Seeking Alpha
Read Now
Media
Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal
May 16, 2023
San Francisco Business Times
Read Now
Press Release
Growing East Bay biotech Scribe Therapeutics lines up potential $1.5 billion CRISPR deal
May 16, 2023
San Francisco Business Times
Read Now
Press Release
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 2, 2023
Read Now
Press Release
Scribe Therapeutics Announces Oral Presentation at 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 2, 2023
Read Now